← All trials
NCT00393679
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2007
- Primary completion
- Dec 1, 2009
- Completion date
- Dec 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 4112
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Institute of Tropical Medicine, BelgiumLead sponsor
- Centre MurazCollaborator
- Tropical Diseases Research Centre, ZambiaCollaborator
- Albert Schweitzer HospitalCollaborator
- Mbarara University of Science and TechnologyCollaborator
- University of TuebingenCollaborator
- University of LiverpoolCollaborator
- Government of MozambiqueCollaborator
- University of AntwerpStudy director
- East African Network for Monitoring Antimalarial TreatmentCollaborator
- University of CalabarCollaborator
- Uganda Malaria Surveillance ProjectCollaborator
- University of BarcelonaCollaborator
- Government of RwandaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.